The hunt is on for a dry eye disease (DED) therapy to replace Allergan plc's blockbuster, Restasis (ciclosporin), which the Dublin-based firm sought to shield behind the protective estate of 27 patents, including six famously assigned in 2017 to the Saint Regis Mohawk Tribe and then licensed back in perpetuity, seeking to prevent their expiry in 2024.